MBX Biosciences, Inc. MBX
Set alert
At close · Oct 30
After hours · Oct 30, 4:15 PM ET
- YTD
- +77.14%
- 1 year
- +156.40%
- Open
- 53.72
- Prev close
- 54.54
- Mkt cap
- 2.69B
- Vol
- 667.27K
- Avg vol
- 510.80K
- EPS
- -2.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 52.29
- High
- 56.52
- Forward P/E
- -14.01
- Beta
- 0.10
- Short ratio
- 6.96
- Inst. own
- 116.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 58.03
- 200-d avg
- 45.52
- 1y target
- 95.70
5D chart
Signals (86)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 4:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 4:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:30 PM | 6 days ago |
| RSI: Overbought | Oct 26, 1:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
1 week ago accessnewswire.com
Microbix Attending & Presenting at IPVS 2026
Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life…
2 weeks ago globenewswire.com
MBX Biosciences to Participate in Upcoming November Investor Conferences
CARMEL, Ind. and BURLINGTON, Mass.
-
2 weeks ago benzinga.com
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
1 month ago defenseworld.net
MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $55.93 and last traded at $55.84. 88,613 shares were traded during…
1 month ago benzinga.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
1 month ago defenseworld.net
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE bought a new position in MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
1 month ago seekingalpha.com
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy…
1 month ago seekingalpha.com
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago fool.com
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
1 month ago fool.com
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
1 month ago globenewswire.com
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
1 month ago globenewswire.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
CARMEL, Ind. and BURLINGTON, Mass.
1 month ago defenseworld.net
Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX
Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
-
2 months ago benzinga.com
MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
2 months ago globenewswire.com
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
-
2 months ago benzinga.com
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
2 months ago accessnewswire.com
Microbix Reports Results for Q3 Fiscal 2026
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator,…
-
2 months ago benzinga.com
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
-
2 months ago benzinga.com
MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.63) by 23.81 percent. This is a 34.48 percent decrease over losses of…
3 months ago defenseworld.net
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00.…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
3 months ago defenseworld.net
MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of…
3 months ago benzinga.com
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
3 months ago defenseworld.net
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…
-
3 months ago benzinga.com
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of…
3 months ago globenewswire.com
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
3 months ago seekingalpha.com
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables…
4 months ago seekingalpha.com
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
4 months ago benzinga.com
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide…
4 months ago benzinga.com
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
4 months ago benzinga.com
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.
-
4 months ago benzinga.com
MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trialResults consistent with restoration of systemic PTH activity through serum calcium
-
5 months ago benzinga.com
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70
Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86
Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.
-
5 months ago benzinga.com
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.
-
5 months ago benzinga.com
MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Pharmacokinetic Profile Supporting Potential For Once-Monthly Dosing And Competitive Weight Loss In First MAD Cohort
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)MBX 4291 generally well…
-
5 months ago benzinga.com
MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 28.17 percent increase over losses of…
-
7 months ago benzinga.com
MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of…
-
8 months ago benzinga.com
Earnings Scheduled For February 12, 2026
Earnings Scheduled For February 12, 2026
-
9 months ago benzinga.com
Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
-
9 months ago benzinga.com
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
-
9 months ago benzinga.com
UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60
UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.
9 months ago benzinga.com
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
-
10 months ago benzinga.com
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $45 to $50.
-
10 months ago benzinga.com
Earnings Scheduled For December 18, 2025
Earnings Scheduled For December 18, 2025
-
11 months ago benzinga.com
Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18
Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.